Skip to main content
An official website of the European UnionAn official EU website
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Advances in the Diagnosis and Gene Therapy of Congenital dyserythropoietic Anemia

Project description

Novel tools for the diagnosis and treatment of congenital anemias

Congenital dyserythropoietic anemias (CDA) are a group of hereditary hematological diseases (HHD) characterised by congenital anemia with ineffective erythropoiesis. The scope of the EU-funded ADGENTHE-CDA project is to develop tools for the diagnosis and treatment of CDA focussing on state-of-the-art technologies. Scientists will identify novel genes and establish a genetic panel for CDA diagnosis using the revolutionary next-generation sequencing (NGS) technology. This will improve the opportunity for prompt treatment sparing patients from unwanted side effects. Through cellular CDA models and gene therapy tools, the project will pave the way for novel and more effective therapies.

Objective

The emergence of next-generation sequencing technology (NGS) has revolutionized the diagnosis of genetic diseases including hereditary haematological diseases (HHD) providing a fast and accurate diagnosis, which ultimately leads to health improvement in these patients, as effective treatments are earlier provided, avoiding unwanted and detrimental aspects such as iron toxicity. Gene therapy is starting to be successfully applied in HHD. BloodGenetics (BG) S.L. has previously identified new mutations and new causative genes of HHD and nowadays is commercializing NGS-panels for a number of HHD. This proposal will focus in a particular HHD, the Congenital dyserithropoietic anemias (CDA), a bone marrow failure condition characterized by congenital anemia with ineffective erythropoiesis. The general aim of this proposal is to advance in the establishment of state-of-the-art tools for the diagnosis and treatment of CDA. Specifically, we aim to: 1) stablish a new panel including novel identified genes for and improvemnent in CDA diagnosis, 2) develop new engineered cellular models using CRISPR/CAS9 system for CDA modelling and 3) develop gene therapy tools applied to type II CDA in collaboration with International University of Catalunya (UIC) and Center for Energy, Environmental and Technological Research (CIEMAT). We strongly believe that this project will result in the achieving of a faster and more accurate diagnosis of CDA and to advance in the establishment of molecular tools for CDA gene therapy, which overall will dramatically improve patients quality of life.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Coordinator

BLOODGENETICS SL
Net EU contribution
€ 172 932,48
Address
VERGE DE GUADALUPE 18
08950 Esplugues De Llobregat
Spain

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 172 932,48